Come meet Panna Sharma, CEO of AI firm Lantern Pharma (NASDAQ: LTRN). His presentation is titled "How AI Has Lit A Revolution in Longevity, Healthcare & Medicine." It is sure to be interesting and thought provoking and will prove to be great insight for all.
Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.(NASDAQ: LTRN), an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Lantern's proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, they have accelerated the development of their growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, their newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. Their lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. They have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of their promising therapies for CNS and brain cancers, many of which have no effective treatment options. Their AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
Learn more about how Lantern is transforming the lives of cancer patients by leveraging Artificial Intelligence and Machine Learning in order to stratify patients into responders and non-responders and more deeply understand how to personalize and develop targeted cancer therapies. This, in turn, significantly reduces the timeline and cost of treatment.